News Article

Dr Leonid Shapiro, Managing Partner at Candesic took to the stage for an evening of inspiration and learning in London on Friday last week to discuss the hot topic of AI in drug development.

Candesic was delighted to sponsor the BitePharma Summit and support its mission to train pharma executives in business so they can rise to senior positions in large pharma companies.

Dr Leonid, Ismael Gauci (Senior Director, Roche), Nelli Morgulchik (Investor, Hummingbird Ventures) and Anthony Finbow (Former CEO, Eagle Genomics) explored the expectations of increased partnerships between pharmaceutical firms, technology behemoths, and pioneering startups as AI revolutionizes the landscape of drug discovery and development.

An engaged audience of industry professionals, healthcare experts, and academics enjoyed hearing about advanced AI applications in drug discovery and target identification, and the ethical considerations and regulatory hurdles involved in this sector.

Another discussion led by Zeinab Sulaiman (Practice Leader, Sorcero) included Philip Cruz (Medical Director UK, Moderna), Dr Faiz Shivji (Global Commercial Strategy Director, AstraZeneca) and Ravi Pattanshetty (Medical Director, Perspectum). This panel explored the evolving role of Medical Affairs in the pharmaceutical industry and its transition from a support function to a strategic driver.

Many thanks to the organizers, and all who attended. Anyone present who still has questions should not hesitate to get in touch.

To find out more about Candesic’s work in this area contact Dr Leonid on LinkedIn or drop us an email at [email protected].